Limited Distribution Deals Announced
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
January 26, 2023
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
The FDA recently approved a biologics license application (BLA) for a new infused therapy, Briumvi from TG Therapeutics, Inc., indicated for the treatment of relapsing
Earlier this month the FDA approved a new infused therapy, Leqembi (lecanemab-irmb) from Eisai R&D Management Co., Ltd., indicated for the treatment of Alzheimer’s disease. Therapy
The FDA recently approved a novel gene therapy, Adstiladrin (nadofaragene firadenovec-vncg) from Ferring Pharmaceuticals A/S, indicated for the treatment of adult patients with high-risk Bacillus
The FDA recently approved a new antiviral therapy regimen, Sunlenca (lenacapavir) from Gilead Sciences, indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults
So, can you easily explain the differences between a chemically synthesized drug and a biologic? You might be surprised how difficult that has become. The
We know that there are a limited number of specialty pharmacies in the US. A small number of customers makes it hard for any new product
The FDA recently approved a novel, ORAL monotherapy treatment, Rezlidhia (olutasidenib) from Rigel Pharmaceuticals, Inc., to treat adult patients with relapsed or refractory (R/R) acute
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
Rigel Pharmaceuticals recently received the green light from the FDA for their oral IDH1 inhibitor, REZLIDHIA™ (olutasidenib). REZLIDHIA™ is indicated for treatment of acute myeloid
